{"public_id":"cl_0117b344a31abe9c4d9a1dcd6354e035","status":"active","superseded_by_public_id":null,"corpus_id":12885091,"text":"Mean serum adiponectin concentration in the Parkinson's disease cohort was 9.59 ± 5.9 μg/mL, with an interquartile range of 5.92–12.9 μg/mL.","confidence":0.99,"paper":{"corpus_id":12885091,"title":"Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients","url":"https://sah.borca.ai/papers/12885091"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.99,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_a2a159fa809fe5e51a1fd2ac39d2472a","name":"serum adiponectin concentrations","description":"The amount of adiponectin measured in blood serum.","types":["biomarker"],"url":"https://sah.borca.ai/concepts/co_a2a159fa809fe5e51a1fd2ac39d2472a"},{"public_id":"co_d98f5bc54504f03b9da82c7c524fdbe1","name":"Parkinson's disease cohort","description":"The set of Parkinson's disease patients included in the serum measurement study.","types":["patient cohort"],"url":"https://sah.borca.ai/concepts/co_d98f5bc54504f03b9da82c7c524fdbe1"},{"public_id":"co_fd8e61a5c31fe7ac774298aa488e4194","name":"nutritional status assessment","description":"A clinical evaluation of body weight and nutritional condition, including biomarker measurement.","types":["assessment"],"url":"https://sah.borca.ai/concepts/co_fd8e61a5c31fe7ac774298aa488e4194"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_0117b344a31abe9c4d9a1dcd6354e035"}